Table 1.

Demographics with Univariate and multivariate analysis of clinical variables as part of Phase I of the Neo-V and FLAIM machine learning frameworks.

			Univariate			Multivariate
		n = 1214 (n, affected) and Ranges	p-value	HR	95 %CI	p-value	HR	95 %CI
Demographics	AGE	range (19–96 years)	<0.001*	1.04	1.03–1.06	–	–	–
	Age > 50 years	755	<0.001*	3.15	1.81–5.50	–	–	–
	Age > 65 years	336	<0.001*	2.43	1.72–3.44	–	–	–
	Female	467	0.489	0.88	0.61–1.27	–	–	–
	Readmission	46	0.147	0.05	0.01–2.95	0.951	0.001	0.01–3.40E+164
	Mortality	130 (10.7%)	–	–	–	–	–	–
Blood Grouping	A-	6	0.289	2.91	0.41–20.90	0.553	1.822	0.26–13.18
	A+	132	0.642	0.88	0.51–1.51	0.561	0.852	0.5–1.47
	B-	19	0.332	1.64	0.60–4.45	0.858	1.098	0.4–3.02
	B+	233	<0.05*	1.5	1.03–2.18	0.051	1.459	1–2.13
	O-	13	0.27	0.04	0.00–11.71	0.947	0.001	0.01–2.07E+130
	O+	183	0.224	1.28	0.86–1.90	0.25	1.262	0.85–1.88
	AB-	6	<0.05*	3.88	1.23–12.27	<0.001*	7.634	2.39–24.48
	AB+	48	<0.05*	2.55	1.29–5.04	<0.001*	2.483	1.26–4.93
Comorbidities	Chronic kidney disease	71	<0.001*	3.45	2.08–5.72	<0.001*	2.737	1.63–4.61
	Chronic liver disease	13	0.15	2.32	0.74–7.33	0.125	2.467	0.78–7.82
	Chronic obstructive lung disease	14	<0.05*	2.93	1.19–7.21	0.163	1.918	0.77–4.79
	Diabetes	441	<0.05*	1.45	1.03–2.05	0.261	1.224	0.87–1.74
	Hypertension	521	0.58	1.41	0.99–2.01	0.493	1.137	0.79–1.64
	Ischemic heart disease	158	<0.001*	2.24	1.62–3.62	<0.05*	1.801	1.19–2.73
	Other Comorbidities	571	<0.05*	1.76	1.24–2.48	<0.05*	1.721	1.21–2.45
Symptoms	Asymptomatic	87	0.177	0.38	0.12–1.27	0.269	0.497	0.15–1.72
	Chest pain (non-cardiac)	56	0.252	1.63	0.71–3.71	0.434	1.395	0.61–3.21
	Cough	522	0.110	0.76	0.54–1.07	0.28	0.823	0.58–1.18
	Fatigue/lethargy	52	0.793	1.15	0.42–3.12	0.63	0.78	0.29–2.14
	Fever	768	<0.001*	0.56	0.39–0.79	<0.05*	0.568	0.4–0.81
	Gastrointestinal symptoms	93	0.875	0.94	0.42–2.14	0.626	0.813	0.36–1.88
	Headache	16	0.367	0.05	0.01–34.53	0.953	0.001	0.01–4.24E+150
	Hemoptysis	9	0.609	0.05	0.01–5037.35	0.961	0	0–1.48E+166
	Malaise	83	0.976	0.99	0.41–2.43	0.537	0.752	0.31–1.87
	More than 2 symptoms	901	0.975	1.01	0.66–1.56	0.817	0.95	0.62–1.47
	Myalgia	28	0.284	1.88	0.6–5.94	0.221	2.06	0.65–6.54
	Nasal obstruction	2	0.788	0.05	0.01–157108055.1	0.969	0.001	0.01–4.22E+198
	Other symptoms	321	<0.001*	1.97	1.38–2.8	<0.05*	1.66	1.16–2.38
	Pneumothorax (clinical/radiological)	22	<0.05*	2.00	1.17–3.43	<0.05*	2.014	1.18–3.46
	Rhinorrhea	7	0.502	0.05	0.01–327.09	0.964	0.001	0.01–1.70E+200
	Sore throat	58	0.240	0.51	0.16–1.59	0.637	0.758	0.24–2.41
	Sputum	29	0.070	2.03	0.95–4.35	0.247	1.576	0.73–3.41
Clinical	Acute Kidney Injury	179	<0.001*	2.95	2.08–4.18	<0.001*	2.465	1.74–3.51
	ARDS/Respiratory failure	147	<0.001*	2.81	1.96–4.03	<0.001*	2.527	1.77–3.63
	Septic Shock	49	<0.001*	5.05	3.43–7.43	<0.001*	4.299	2.91–6.37
	Shock Liver	3	<0.001*	11.63	2.84–47.73	<0.001*	11.476	2.77–47.68
	Shortness of breath	570	<0.001*	1.81	1.24–2.62	<0.001*	1.96	1.35–2.86
Point of Care	Special care unit	308	0.355	1.18	0.84–1.68	0.577	1.106	0.78–1.58
	Days spent in the ICU	Range (0–20 days)	0.187	1.03	0.99–1.07	0.133	1.029	1–1.07
	Intensive care unit (ICU)	106	<0.001*	2.71	1.88–3.92	<0.001*	3.241	2.22–4.74
	Number of admissions ICU during current hospitalization	Range (0–2)	<0.001*	1.78	1.3–2.43	<0.001*	2.066	1.49–2.87
Radiology	Bilateral chest X-ray abnormalities	753	0.484	1.14	0.8–1.64	0.34	1.195	0.83–1.72
	Unilateral chest X-ray abnormalities	131	0.911	0.97	0.56–1.7	0.997	0.999	0.58–1.75
Day One labs	Abnormal blood lymphocyte count	378	<0.001*	3.02	1.74–5.26	<0.001*	2.786	1.6–4.86
	Abnormal blood neutrophil count	1044	<0.05*	2.5	1.17–5.36	<0.05*	2.657	1.24–5.7
	Abnormal platelets count	363	<0.05*	1.43	1.01–2.03	<0.05*	1.413	1–2.01
	Abnormal serum albumin	49	0.296	1.45	0.73–2.87	0.207	1.552	0.79–3.07
	Abnormal serum ALT	946	0.380	1.23	0.78–1.95	0.475	1.183	0.75–1.88
	Abnormal serum APTT	347	0.217	1.26	0.88–1.81	0.137	1.32	0.92–1.9
	Abnormal serum bilirubin	69	0.587	0.82	0.4–1.69	0.33	0.699	0.34–1.42
	Abnormal serum BUN	382	<0.001*	3.15	2.19–4.52	<0.001*	2.784	1.94–4.01
	Abnormal serum calcium	387	0.596	0.91	0.62–1.33	0.633	0.91	0.62–1.35
	Abnormal serum creatinine	373	<0.001*	3.21	2.24–4.6	<0.001*	2.73	1.9–3.94
	Abnormal serum hematocrit	505	<0.001*	1.87	1.33–2.65	<0.05*	1.808	1.26–2.61
	Abnormal serum hemoglobin	879	<0.05*	1.67	1.08–2.58	<0.05*	1.63	1.05–2.55
	Abnormal serum INR	198	<0.001*	3.38	2.38–4.8	<0.001*	3.243	2.28–4.63
	Abnormal serum LDH	751	0.597	1.11	0.77–1.58	0.806	1.047	0.74–1.5
	Abnormal serum magnesium	268	0.535	0.88	0.57–1.35	0.841	0.957	0.63–1.48
	Abnormal serum phosphorus	32	0.893	1.08	0.4–2.91	0.58	0.752	0.28–2.07
	Abnormal serum potassium	241	0.886	0.97	0.64–1.49	0.678	0.914	0.6–1.41
	Abnormal serum procalcitonin	523	0.312	1.2	0.85–1.69	0.485	1.132	0.8–1.61
	Abnormal serum PT	378	<0.05*	1.5	1.05–2.15	<0.05*	1.787	1.24–2.59
	Abnormal serum sodium	458	0.250	1.23	0.87–1.73	0.501	1.127	0.8–1.6
	Abnormal white cell count	455	<0.001*	2.08	1.45–2.96	<0.001*	2.089	1.47–2.98
Treatment	Anti-malarial	2	0.385	2.4	0.34–17.27	0.587	1.73	0.24–12.51
	Anti-viral drugs	99	0.715	0.9	0.51–1.6	0.538	0.835	0.47–1.49
	CRRT	7	<0.05*	2.72	1.19–6.23	0.054	2.287	0.99–5.3
	Hydroxychloroquine	77	0.230	0.61	0.27–1.38	0.336	0.667	0.3–1.53
	Intravenous IgG	6	<0.05*	3.87	1.23–12.23	<0.05*	3.945	1.25–12.49
	Invasive ventilation	74	<0.001*	2.79	1.89–4.1	<0.001*	3.208	2.15–4.79
	Lopinavir/Ritonavir	1	0.616	0.05	0.01–6488.77	0.962	0.001	0.01–6.44E+175
	Non-invasive ventilation (BiPAP/CPAP)	243	<0.001*	1.96	1.38–2.8	<0.001*	1.872	1.32–2.67
	Plasmapheresis	96	0.317	1.25	0.82–1.91	0.234	1.294	0.85–1.98
	Supportive treatment	617	<0.001*	3.89	2.22–6.81	<0.001*	3.507	2.01–6.14
	Symptomatic treatment	1056	<0.05*	0.6	0.36–0.98	0.058	0.613	0.37–1.02
	Systemic steroids	430	0.238	0.8	0.55–1.17	<0.05*	0.657	0.45–0.97